AnorMED Inc.

AnorMED Inc.
visit the site
AnorMED Inc. is a Canadian biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products for the treatment of a variety of diseases, including cancer, HIV and inflammation. Our strength lies in our medicinal chemistry capabilities that involve the application of chemistry, biochemistry and biology to generate novel chemical compounds (small molecules) with distinct pharmacological properties and therapeutic potential. Currently, we have several distinct drug candidates at various stages of development. These are divided into two categories: core products and programs, which are the focus of our in-house efforts and expense; and additional products, which are being developed by partners. AnorMED's core products and programs include: AMD3100, a stem cell mobilizer; AMD070, a new anti-HIV agent; and a research program focused on the discovery of drug candidates that target a specific class of receptors expressed on the surface of immune system cells called chemokine receptors. Specifically, the CXCR4 and CCR5 receptors that are known to be involved in a variety of diseases. The latter is a discovery program that provides further opportunities for long-term future growth. The additional products in our portfolio include: FOSRENOL, a late stage drug candidate for kidney failure patients to treat hyperphosphataemia; NX473, a cancer chemotherapy agent; the HYNIC linker, a tool for medical imaging; and Atiprimod, a potential anti-cancer agent. Our long-term business strategy involves building upon our internal drug discovery and clinical development capabilities to support the advancement of our most promising therapeutic candidates through late stage clinical trials, and to build a sales and marketing capability for select products in specific territories contingent upon available resources. We will seek to partner our product candidates at various stages of development where additional expertise or resources in clinical development and/or sales and marketing are required and reasonable commercial terms can be secured. The more advanced a product is before partnering, the better positioned we should be to negotiate terms which could include up-front and milestone payments, funding from the partner to cover all or a portion of ongoing development costs, as well as a share of revenues based on net product sales. We will also consider partnering arrangements that will enable AnorMED to participate in the marketing of the drug candidates in certain geographical areas along with arrangements that may provide a greater share of revenues in exchange for participation in the later stage development of the drug candidate. We may also evaluate opportunities to in-license a product or program to build on our core capabilities and pipeline, and will utilize alliances and strategic partnerships to expand clinical, regulatory and product development capabilities. In the short-term, we are focused on moving our lead product candidates, AMD3100 and AMD070, through clinical trials. We are currently engaged in a number of pre-commercial activities with AMD3100. In addition we are evaluating the opportunity to create our own sales and marketing team to support North American sales of this drug candidate by AnorMED. We are also conducting a series of preclinical studies with our collaborators to study the potential role AMD3100 may play in tissue repair and cancer. We expect that we will seek a partner for the worldwide commercialization of AMD070 once we have established clinical proof of principle. We will seek partnerships to support and expand the development of our drug candidates outside of North America and if we feel that we are constrained in development by available financing, resources or expertise. In addition, we are working toward identifying a clinical candidate in our CCR5 program for the treatment of HIV. Research and development within the chemokine program has resulted in the creation of a series of unique compounds targeting CXCR4 and CCR5, among other receptors. We plan to identify lead compounds from this chemokine inhibitor program to test in preclinical studies for oncology, inflammation and HIV. Collaborations and partnerships for these programs, or specific parts of these programs, will also be explored. We will continue to evaluate external product and program opportunities consistent with our business strategy and complimentary to our areas of expertise. In the context of potential growth opportunities within our own research programs we will evaluate product opportunities based on: technical/ scientific merit and challenges; business case; and resource requirements. We have several areas of activity with the potential to create substantial near-term value should we obtain positive results in our clinical programs or secure a corporate partnership that would provide third party validation of our programs and the resources to move our product candidates forward to commercialization. In addition, we are anticipating the approval and market launch of FOSRENOL this year which would provide a source of income to AnorMED.

Therapeutic drugs

5
0
12/8/2013

Rate this site

Related Sites

Note

Not found any data